Lymphangiogenesis is an important process that contributes to the spread of cancer. Here we show that insulin-like growth factors 1 (IGF-1) and 2 (IGF-2) induce lymphangiogenesis in vivo. In a mouse cornea assay, IGF-1 and IGF-2 induce lymphangiogenesis as detected with LYVE-1, a specific marker for lymphatic endothelium. angiogenesis ͉ insulin-like ͉ growth factor family ͉ vascularization ͉ tumor growth ͉ metastasis
M
etastasis is a major cause of cancer mortality and represents the invasive nature of malignant cells. Tumor cells metastasize by hematogenous and lymphogenous pathways. In certain types of cancers, such as breast cancer, lymphatic metastasis occurs in the early stages of cancer development, and malignant cells can be further spread from the lymphatic system to the circulatory system (1) . Recent studies demonstrate that peritumoral and intratumoral lymphatic vessels are critical structures for lymphatic metastasis (2, 3) . Like blood vessels, lymphatic vessels in the adult remain quiescent under normal physiological conditions. The switch to a lymphangiogenic phenotype in tumors is likely to require up-regulation of expression of lymphangiogenic factors and down-regulation of expression of lymphangiogenic inhibitors (4) .
Recently, a number of lymphangiogenic factors have been identified (5) (6) (7) (8) (9) (10) (11) . Members of the vascular endothelial growth factor (VEGF) family are probably the best-studied factors because VEGF receptor-3 (VEGFR-3) is specifically expressed on lymphatic endothelial cells (LECs) (12, 13) . Two lymphangiogenic factors, VEGF-C and VEGF-D, interact with VEGFR-3 and VEGFR-2, leading to lymphangiogenesis and hemangiogenesis (13, 14) . Recent studies have shown that VEGF-C͞ VEGF-D͞VEGFR-3-mediated signals are critical for sprouting of the first lymphatic vessels from the developing veins in the embryo, suggesting that this system is essential for differentiation of endothelial progenitor cells into the lymphatic lineage (15) . VEGF-C and VEGF-D are also widely expressed in a variety of malignant tissues, and they have both been shown to mediate lymphatic metastasis when expressed at high levels (16, 17) . In addition to VEGF-C and VEGF-D, VEGF-A has also been found to act as a potent lymphangiogenic factor in vivo (7, 8, 10) . Inflammatory cells, such as macrophages, are recruited to tumors by a wide range of tumor cell-derived cytokines and growth factors, including VEGF-A. At the tumor site, the inflammatory cells play a critical role in mediating recruited lymphangiogenesis most likely through the secretion of several lymphangiogenic cytokines (7) .
In addition to members of the VEGF family, fibroblast growth factor 2 (FGF-2), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and platelet-derived growth factors (PDGFs) have also been shown to induce lymphangiogenesis in vivo (5, 6, 9, 11, 18, 19) . Although FGF-2 directly stimulates LEC activity in vitro, its in vivo lymphangiogenic effect is probably mediated via the activation of VEGFR-3 signaling pathway (6, 9) . Deletion of the Ang-2 gene in mice results in defective lymphatic vessel patterning, suggesting that Ang-2 is required for lymphatic vessel remodeling (18, 20) . Similarly, Ang-1 has been demonstrated to bind to the Tie-2 receptor and thereby induce lymphangiogenesis (11) . Members of the PDGF family act as direct lymphangiogenic factors by interacting with their receptors, PDGF-R-␣ and -␤, both of which are expressed on isolated LECs, although any indirect effects on stimulation of lymphangiogenesis cannot be excluded (5) .
Genomic instability of tumor cells can lead to expression of multiple angiogenic-and lymphangiogenic factors (4, 21, 45) . Members of the insulin-like growth factor (IGF) family are frequently expressed in many types of tumors associated with malignant progression and poor prognosis (22) (23) (24) (25) (26) (27) . The IGF system consists of two ligands (IGF-1 and IGF-2), two transmembrane receptors (IGF-1R and IGF-2R), and several IGFbinding proteins (IGFBPs). The IGFBPs may modulate the biological activity of IGFs (28) . There is increasing evidence that IGF-1 might contribute to cancer development by regulating cell proliferation, differentiation, and cell death (29) (30) (31) . Both IGF-1 and IGF-2 induce angiogenesis in several in vitro and in vivo systems (32) (33) (34) (35) . IGF-1R, the functional receptor for IGFs, is expressed on isolated hemovascular endothelial cells and newly formed blood microvessels (36, 37) . In addition to its direct role in stimulation of hemangiogenesis, the IGF-1͞IGF-1R signaling system can also up-regulate VEGF expression and thus indirectly induce neovascularization (24, (38) (39) (40) . In contrast however, nothing is known currently about the roles of IGFs and their receptors in the lymphatic vasculature. Here we show that IGFs can indeed induce lymphangiogenesis both in vitro and in vivo and discuss the possible involvement of these factors in lymph node metastasis.
Methods
Reagents and Animals. Female and male 6-to 7-week-old C57BL͞6 mice were acclimated and caged in groups of six or less. Animals were anaesthetized by an injection of a mixture of dormicum and hypnorm (1:1) before all procedures and killed by a lethal dose of CO 2 followed by cervical dislocation. All animal studies were reviewed and approved by the animal care and use committee of the North Stockholm Animal Board (for detailed description of reagents, see Supporting Methods, which is published as supporting information on the PNAS web site).
Mouse Corneal Neovascularization Assay. The mouse corneal angiogenesis assay was performed according to procedures described in ref. 5 . For a detailed description, see Supporting Methods.
Isolation of Primary Human and Murine Dermal LECs. Human LECs were isolated by outgrowth from commercial dermal microvascular endothelial cells purchased from PromoCell (Heidelberg, Germany) using the method described in Nisato et al. (46) . Murine dermal LECs were selected from the collagenase digested skin of C57BL͞6 mouse pups (2-3 days old) using a rat anti-mouse LYVE-1 mAb with MACS microbeads and grown on collagen-coated vessels in microvascular endothelial growth medium (EGM-2 MV; Cambrex, East Rutherford, NJ). Both human and murine endothelial cells were cultured in EGM-2 MV containing 5% FBS on either gelatin-coated (Sigma) or type I collagen-coated (BD Biosciences, Franklin Lakes, NJ) plasticware, respectively. Proliferation Assay. Primary LECs were seeded at a density of 1 ϫ 10 4 cells per well in 24-well plates in endothelial cell basal medium 2 supplemented with 5% FCS and 100 ng͞ml of recombinant IGF-1, IGF-2, or VEGF-C. Untreated cells served as a negative control. The cells were incubated at 37°C for 72 h before being trypsinized, resuspended in Isoton II solution (Beckman Coulter), and counted in a Coulter Counter. Four replicate samples were used for each experiment, and the experiment was repeated twice.
LEC Motility Assay.
The motility responses of human and murine LECs to recombinant IGF-1 or IGF-2 were assayed by using a modified Boyden chamber technique described in ref. 5 . For a detailed description, see Supporting Methods.
Whole-Mount Staining and Confocal Analysis. Growth factorimplanted mouse eyes were double-stained for CD31 and LYVE-1 by using a whole-mount staining protocol recently published (5) . For a detailed description of these procedures, see Supporting Methods.
Expression of IGF-1R.
Monolayers of primary human LECs were cultured on cover slips in 12-well plates. Cells were fixed in 3% paraformaldehyde followed by a careful wash in PBS. After blockage in 20% serum, the cells were incubated with a rabbit anti-mouse IGF-1R antibody diluted in 0.3% Triton X-100 PBS. To avoid any nonspecific signal from the secondary antibody the cells were blocked again in 20% (vol͞vol) rabbit serum before revealing the signal with a donkey anti-rabbit Alexa Fluor 488 antibody (Molecular Probes) diluted in 0.3% Triton X-100 in PBS. After washing, the samples were mounted with VECTASHIELD mounting medium (Vector Laboratories) and analyzed with a fluorescent microscope.
RT-PCR. RT-PCR was performed to amplify IGF-1R and IGF-2R by using cDNAs prepared from human or mouse LECs as templates. Primer sequences included the following: human IGF-1R, 5Ј-GAAGTGGAACCCTCCCTCTC-3Ј (forward) and 5Ј-CTTCTCGGCTTCAGTTTTGG-3Ј (reverse) (product size, 241 bp); human IGF-2R, 5Ј-AAGGGGACAACTGTGAG-GTG-3Ј (forward) and 5Ј-ACATGAGGAGACCACCTTGG-3Ј (reverse) (product size, 179 bp); mouse IGF-1R, 5Ј-CAAGCT-GTGTGTCTCCGAAA-3Ј (forward) and 5Ј-TGATGAGATC-CCGGTAGTCC-3Ј (reverse) (product size, 209 bp); and mouse IGF-2R, 5Ј-GTGTCCTCTGGGTGTGGACT-3Ј (forward) and 5Ј-CTCCTCCTTGCTGACCTTTG-3Ј (reverse) (product size, 241 bp). The PCR-amplification program consisted of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min for a total of 35 cycles.
DNA Microarray Analyses of Primary Human and Murine
LECs. cRNA targets for hybridization to human or murine DNA microarrays were prepared by reverse transcription from total cellular RNA extracted from cultured primary human or murine LECs by using a commercial RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Targets were then labeled with biotin before fragmentation according to standard Affymetrix protocols. Hybridization to Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays or to Affymetrix GeneChip Mouse Expression Set 430 arrays was carried out at the Cancer Research UK Microarray Facility (Paterson Institute for Cancer Research, Manchester, UK). The RMA method (part of the BIOCONDUCTOR package) was used to normalize the data with default parameters. Data were interrogated for absolute expression levels of individual transcripts in terms of signal intensities and rated as present or absent according to detection P cutoff values of Ͻ0.04 or Ͼ0.06, respectively, using Affymetrix MICROARRAY SUITE and GENECHIP OPERATING Software.
Immunoblot Analysis. Monolayers of human LECs were stimulated with IGF-1 or IGF-2 at a concentration of 100 ng͞ml for various time points. After extensive washing with PBS, cells were lysed in 20 mM Hepes buffer, pH7.1, supplemented with 150 mM NaCl͞50 mM NaF͞1% Triton X-100 (wt:vol)͞30 mM Na 4 P 2 O 7 ͞5 M ZnCl 2 ͞20 mM ␤-glycerophosphate͞10 mM 4-nitrophenyl phosphate͞1 mM DTT͞100 M Na 3 VO 4 ͞0.5 mM PMSF (41) . Cell lysates were centrifuged, and the supernatants were collected for protein determination by using a modified Lowry method (Bio-Rad) with BSA as standard. Equal amounts of each sample were loaded onto 4-20% acrylamide SDS͞PAGE gradient gels (NOVEX, San Diego). Proteins were transferred onto nitrocellulose membranes (Schleicher & Schuell), which were subsequently blocked overnight at room temperature with 2.5% BSA-PBST (140 mM NaCl͞2.7 mM KCl͞8.1 mM Na 2 HPO 4 , pH 7.3͞0.3% Triton X-100), followed by incubation with the appropriate antibodies at 4°C overnight. After extensive washing with PBST, membranes were incubated for about 1 h at room temperature with peroxidase-coupled secondary antibodies. After further washing, immunoreactive signals were revealed by chemiluminescence.
Statistical Analyses. Statistical analysis of the results was carried out by using a standard Student two-tailed t test using Microsoft EXCEL 5 . P values Ͻ0.05, Ͻ0.01, and Ͻ0.001 were deemed as significant, highly significant, and extremely significant, respectively.
Results

IGF-1 and IGF-2 Induce Hemangiogenesis.
A mouse corneal micropocket angiogenesis model was used to study hemangiogenic and lymphangiogenic activity of IGFs. Under physiological conditions, the cornea is an avascular organ, thus facilitating studies into the formation of new blood and lymphatic vessels induced by various stimuli. Implantation of IGF-1 or IGF-2 together with a slow release polymer in the mouse cornea resulted in relatively robust angiogenic responses ( Fig. 1 B and C) . IGF-1-and IGF-2-induced blood vessels consisted of well organized vascular networks with distinct blood microvessels growing toward the implanted factors. The patterns of IGF-1-and IGF-2-induced vessels were similar to those induced by FGF-2 (Fig. 1E) . In contrast, VEGF-A-induced vascular networks were composed of disorganized vascular plexuses due to fusion of multiple blood capillaries͞microvessels into large pseudoluminal structures (Fig. 1D) . Comparison of blood vascularization areas demonstrated FGF-2 as the most potent angiogenic factor, whereas IGF-1, IGF-2, and VEGF-A exhibited similar effects in this assay system (Fig. 1 F-H ). These findings demonstrate that IGF-1 and IGF-2 are potent hemangiogenic factors in vivo.
Stimulation of Lymphangiogenesis. Lymphatic vessels express several specific markers, including LYVE-1, podoplanin, prox-1, and VEGFR-3 (4, 14) . We previously reported LYVE-1 to be specifically expressed on newly formed lymphatic vessels but not on blood vessels in the mouse corneal model (5) . Hence, we used LYVE-1 as a specific maker for detection of lymphatic vessels in the present study. Interestingly, both IGF-1 and IGF-2 potently stimulated lymphatic vessel growth in the mouse cornea (Fig. 2  B and F) . These newly formed LYVE-1-positive lymphatic vessels were generally negative for CD31, unlike newly formed blood vessels, which stained strongly for CD31 (Fig. 2 A, C-E, G, and H). The lymphatic vessels induced by IGF-1 or IGF-2 had vascular ''tree-like'' structures that consisted of lymphatic capillaries sprouting from large stems and preexisting limbal lymphatic vessels (Fig. 2 B and F) . Similarly, FGF-2, a known lymphangiogenic factor, also exhibited robust hemangiogenic and lymphangiogenic effects in this assay, albeit the lymphangiogenic effect of FGF-2 seemed to be more potent than that of IGF-1 and IGF-2 ( Fig. 2 I-L ). These data demonstrate that IGF-1 and IGF-2 are lymphangiogenic factors.
Role of VEGF-C͞VEGF-D͞VEGFR-3 Pathway in IGF-1-Induced Lymphangiogenesis.
To investigate whether IGF-1 stimulates lymphangiogenesis directly via its cognate receptor or indirectly via additional factors, we tested the ability of soluble VEGFR-3, a known lymphangiogenic antagonist, to potentially block its lymphangiogenic activity in the cornea pocket assay. The VEGF- C͞VEGF-D͞VEGFR-3 system is the most well characterized direct lymphangiogenic signaling pathway (4, 12) . We previously showed that a VEGFR-3-soluble receptor (sR3) could effectively block VEGF-C-induced lymphangiogenesis when coimplanted in the mouse cornea (5, 9) . The same dose of sR3 known to effectively block the lymphangiogenic activity of VEGF-C did not display any significant inhibitory activity against IGF-1-induced lymphangiogenesis (Fig. 3 B, E, and H) . Similarly, coimplantation with sR3 did not inhibit IGF-1-induced blood vessel growth (Fig. 3 A, D, and G) . These results indicate the likelihood that IGF-1 acts as a direct lymphangiogenic factor by activating a signaling pathway independent from that triggered by the VEGF-C͞VEGF-D͞VEGFR-3 system. However, we cannot exclude the possibility that IGFs might also indirectly stimulate lymphangiogenesis via other signaling systems.
(E). At day 5 after implantation, corneal neovascularization was photographed. (A) Slow-release polymer containing PBS without growth factors was used as a negative control . Arrows in A-E point to the implanted pellets. (F-H) Quantification of vessel length (F), clock-hour (G), and neovascularization area (H).
Detection of IGF Receptors (IGFRs) on Isolated LECs. We next investigated whether the receptors for IGFs are present in lymphatic endothelium, by immunohistochemical staining for IGF-1R protein in cultured primary LECs and by RT-PCR and DNA microarray analysis for IGFR mRNA. As shown in Fig. 4 A and C, anti-IGF-1R antibody specifically recognized IGF-1R expression on primary human LECs, whereas a nonimmune IgG antibody used as a negative control did not reveal significant detectable signals on these cells (Fig. 4 D and F) . Confirming this result, RT-PCR detected mRNAs of IGF-1R and IGF-2R in murine and human LEC RNAs (Fig. 4 G and H) . Likewise, Affymetrix GeneChip analysis demonstrated that IGF-1R and IGF-2R are expressed in isolated LECs from each species (Table  1) . Moreover, several IGFBPs, including IGFBP4-IGFBP7, IGF2BP1, and IGF2BP3, were detected in mouse LECs, and IGFBP3-IGFBP7 were detected in human LECs. These data further demonstrate that IGFs may directly regulate LEC growth via activation of their receptors or modulators of receptor activation.
Direct Effects on Isolated LECs.
To further characterize the effects of IGFs on LECs, we studied their responses in terms of cell proliferation, chemotaxis, and intracellular signaling. Stimulation of human LECs with IGF-1 or IGF-2 led to significantly increased cell proliferation (Fig. 5D) . IGF-1 also induced chemotaxis of human and mouse LECs in a dose-dependent manner in a modified Boyden chamber assay (Fig. 5 A and B) . Similarly, IGF-2 also exhibited a dose-dependent chemotactic activity on isolated human LECs (Fig. 5C) . Interestingly, sR3 could not block either IGF-1-or IGF-2-induced LEC motility in this cell migration assay (Fig. 5 A-C ). These data demonstrate that IGF-1 acts directly on LECs to induce cell proliferation and migration, both of which are essential steps for lymphangiogenesis. Consistent with cell proliferation and migration activities, IGF-1 stimulated phosphorylation of intracellular signaling components of LECs, including extracellular signal-regulated kinase (ERK; mitogen-activated protein kinase), Akt (protein kinase B), and Src (Fig. 4E) . The induction of phosphorylation of ERK, Akt, and Src by IGF-1 was detectable after 15 min of stimulation with the growth factor and reached a maximum at 60 min. The phosphorylation of these signaling components was still detectable after 120 min of stimulation, albeit slightly decreased levels were observed (Fig. 5E) . Similarly, IGF-2 induced phosphorylation of ERK, Akt, and Src in LECs. Time-course analysis revealed that, although stimulation of ERK by IGF-2 became apparent after 15 min of stimulation, the levels of Akt and Src were barely detectable at this time point (Fig. 5F ). At 30 min after IGF-2 stimulation, maximal phosphorylation of all three components was detected. Comparison of the patterns of IGF-1-and IGF-2-induced phosphorylation showed that IGF-2 induced a delayed activation of Akt and Src, which persisted for a relatively short period. These data show that IGF-1 and IGF-2 are able to induce phosphorylation of intracellular signaling components downstream from the IGFRs.
Discussion
Members of the IGF family are frequently expressed in many solid tumors, and this expression has been correlated with cancer metastasis (22-24, 26, 27, 42) . These findings suggested to us that IGFs might promote lymphangiogenesis. In the present study, we have shown that IGF-1 and IGF-2 indeed act as lymphangiogenic factors, and we provide evidence that this effect is mediated directly by IGFRs present on lymphatic endothelium. First, isolated primary LECs were shown to express mRNA and proteins of IGF-1R or IGF-2R. Second, IGF-1 and IGF-2 were shown to stimulate proliferation and migration of primary human and mouse LECs. Third, IGF-1 or IGF-2 were shown to induce phosphorylation of the protein kinases Akt, Src, and ERK, which are known to transduce cell growth signals in IGF responsive cells. Last, a soluble VEGFR-3 was shown to have no effect on the cell motility of LECs stimulated by IGF-1 or IGF-2 as well as IGF-1-induced lymphangiogenesis in vivo. Together, these findings indicate that IGF-1 and IGF-2 might directly act on LECs to induce lymphangiogenesis. However, we cannot exclude the possibility that IGFs might also have indirect effects in the induction of lymphangiogenesis via other growth factor͞ receptor systems. For example, the IGF-1͞IGF-1R signaling system has been shown to up-regulate both mRNA and protein expression of VEGF-A, a known lymphangiogenistic growth factor (24, (38) (39) (40) 43) . Hence, it is possible that the IGFs could indirectly induce lymphoproliferation via up-regulation of VEGF-A expression (7, 8, 10) . Moreover, the VEGF-C͞VEGF-D͞VEGFR-3 pathway is not the only direct lymphangiogenic signaling system transducing lymphangiogenic signals in LECs. For example, a number of growth factors, including plateletderived growth factor-BB, Ang-1, and Ang-2 have been shown to directly induce lymphangiogenesis in vivo (5, 11, 19, 20) . It is thus possible that IGFs could indirectly induce lymphangiogenesis via these systems. Nevertheless, the effects observed with IGF-1 and IGF-2 on LEC proliferation and migration indicate that they at least have a direct impact on certain steps of lymphangiogenesis.
Positive and negative hemangiogenic regulators are involved in switching on a hemangiogenic phenotype (44) . In similar fashion, switching on lymphangiogenesis in a tumor may represent an imbalance in expression between lymphangiogenic factors and inhibitors. Genomic instability of tumor cells leads to amplified expression of multiple growth factors during malignant progression (45) . Thus, complex regulation might exist in controlling tumor lymphangiogensis and metastasis. Most studied lymphangiogenic factors display hemangiogenic and lymphangiogenic activities, suggesting the existence of crosstalk between blood and lymphatic vessels. Recent studies, however, demonstrate that lymphatic vessels can grow without concomitant hemangiogenesis (6, 45) , suggesting the presence of specific lymphangiogenic factors that remain to be identified.
It is not known whether there is any functional difference between the lymphatic endothelium induced by IGFs or VEGF-C. However, it is highly possible that these two growth factors might produce synergistic stimulatory effects on lymphangiogenesis if they use different signaling pathways in LECs.
The finding that IGF-1 and IGF-2 promote lymphangiogenesis indicates multiple roles of IGFs in promoting tumor growth. Besides cell growth-promoting activity, IGFs are also potent survival factors that may prevent cellular apoptosis of tumor cells, blood vessel endothelial cells, and lymphatic endothelial cells (29) (30) (31) . Thus, development of IGF antagonists may be an important approach for the treatment of cancer and metastasis. The discovery of increasing numbers of lymphangiogenic factors thus suggests that a complex interplay between these factors exists. Accordingly, combinatorial therapeutic approaches targeting common pathways triggered by various factors would, at least in theory, be more effective and hopefully sufficient in blocking lymphatic metastasis. 
